Immunochemotherapy plus lenalidomide for high-risk mantle cell lymphoma with measurable residual disease evaluation
Chemoimmunotherapy followed by consolidative high-dose therapy with autologous stem cell rescue was a standard upfront treatment for fit patients with mantle cell lymphoma (MCL) in first remission; however, treatment paradigms are evolving in the era of novel therapies. Lenalidomide is an immunomodulatory agent with known efficacy in treating MCL. We conducted a single-center, investigator-initiated, phase II study of immunochemotherapy incorporating lenalidomide, without autologous stem cell transplant consolidation, enriching for patients with high-risk MCL (clinicaltrials gov. Identifier: NCT02633137). Patients received four cycles of lenalidomide-R-CHOP, two cycles of R-HiDAC, and six cycles of R-lenalidomide. The primary endpoint was rate of 3-year progression-free survival. We measured measurable residual disease (MRD) using a next-generation sequencing-based assay after each phase of treatment and at 6 months following end-oftreatment. We enrolled 49 patients of which 47 were response evaluable. By intent-to-treat, rates of overall and complete response were equivalent at 88% (43/49), one patient with stable disease, and two patients had disease progression during study; 3-year progression-free survival was 63% (primary endpoint not met) and differed by TP53 status (78% wild-type vs. 38% ALT; P=0.043). MRD status was prognostic and predicted long-term outcomes following R-HiDAC and at 6 months following end-of-treatment. In a high-dose therapy-sparing, intensive approach, we achieved favorable outcomes in TP53- wild-type MCL, including high-risk cases. We confirmed that sequential MRD assessment is a powerful prognostic tool in patients with MCL.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:109 |
|---|---|
| Enthalten in: |
Haematologica - 109(2024), 4 vom: 01. Apr., Seite 1149-1162 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Epstein-Peterson, Zachary D [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Clinical Trial, Phase II |
|---|
| Anmerkungen: |
Date Completed 03.04.2024 Date Revised 04.04.2024 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.3324/haematol.2023.282898 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM361445466 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM361445466 | ||
| 003 | DE-627 | ||
| 005 | 20240404234253.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3324/haematol.2023.282898 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1364.xml |
| 035 | |a (DE-627)NLM361445466 | ||
| 035 | |a (NLM)37646671 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Epstein-Peterson, Zachary D |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Immunochemotherapy plus lenalidomide for high-risk mantle cell lymphoma with measurable residual disease evaluation |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 03.04.2024 | ||
| 500 | |a Date Revised 04.04.2024 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Chemoimmunotherapy followed by consolidative high-dose therapy with autologous stem cell rescue was a standard upfront treatment for fit patients with mantle cell lymphoma (MCL) in first remission; however, treatment paradigms are evolving in the era of novel therapies. Lenalidomide is an immunomodulatory agent with known efficacy in treating MCL. We conducted a single-center, investigator-initiated, phase II study of immunochemotherapy incorporating lenalidomide, without autologous stem cell transplant consolidation, enriching for patients with high-risk MCL (clinicaltrials gov. Identifier: NCT02633137). Patients received four cycles of lenalidomide-R-CHOP, two cycles of R-HiDAC, and six cycles of R-lenalidomide. The primary endpoint was rate of 3-year progression-free survival. We measured measurable residual disease (MRD) using a next-generation sequencing-based assay after each phase of treatment and at 6 months following end-oftreatment. We enrolled 49 patients of which 47 were response evaluable. By intent-to-treat, rates of overall and complete response were equivalent at 88% (43/49), one patient with stable disease, and two patients had disease progression during study; 3-year progression-free survival was 63% (primary endpoint not met) and differed by TP53 status (78% wild-type vs. 38% ALT; P=0.043). MRD status was prognostic and predicted long-term outcomes following R-HiDAC and at 6 months following end-of-treatment. In a high-dose therapy-sparing, intensive approach, we achieved favorable outcomes in TP53- wild-type MCL, including high-risk cases. We confirmed that sequential MRD assessment is a powerful prognostic tool in patients with MCL | ||
| 650 | 4 | |a Clinical Trial, Phase II | |
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Lenalidomide |2 NLM | |
| 650 | 7 | |a F0P408N6V4 |2 NLM | |
| 700 | 1 | |a Drill, Esther |e verfasserin |4 aut | |
| 700 | 1 | |a Aypar, Umut |e verfasserin |4 aut | |
| 700 | 1 | |a Batlevi, Connie Lee |e verfasserin |4 aut | |
| 700 | 1 | |a Caron, Philip |e verfasserin |4 aut | |
| 700 | 1 | |a Dogan, Ahmet |e verfasserin |4 aut | |
| 700 | 1 | |a Drullinsky, Pamela |e verfasserin |4 aut | |
| 700 | 1 | |a Gerecitano, John |e verfasserin |4 aut | |
| 700 | 1 | |a Hamlin, Paul A |e verfasserin |4 aut | |
| 700 | 1 | |a Ho, Caleb |e verfasserin |4 aut | |
| 700 | 1 | |a Jacob, Allison |e verfasserin |4 aut | |
| 700 | 1 | |a Joseph, Ashlee |e verfasserin |4 aut | |
| 700 | 1 | |a Laraque, Leana |e verfasserin |4 aut | |
| 700 | 1 | |a Matasar, Matthew J |e verfasserin |4 aut | |
| 700 | 1 | |a Moskowitz, Alison J |e verfasserin |4 aut | |
| 700 | 1 | |a Moskowitz, Craig H |e verfasserin |4 aut | |
| 700 | 1 | |a Mullins, Chelsea |e verfasserin |4 aut | |
| 700 | 1 | |a Owens, Colette |e verfasserin |4 aut | |
| 700 | 1 | |a Salles, Gilles |e verfasserin |4 aut | |
| 700 | 1 | |a Schöder, Heiko |e verfasserin |4 aut | |
| 700 | 1 | |a Straus, David J |e verfasserin |4 aut | |
| 700 | 1 | |a Younes, Anas |e verfasserin |4 aut | |
| 700 | 1 | |a Zelenetz, Andrew D |e verfasserin |4 aut | |
| 700 | 1 | |a Kumar, Anita |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Haematologica |d 1947 |g 109(2024), 4 vom: 01. Apr., Seite 1149-1162 |w (DE-627)NLM000081892 |x 1592-8721 |7 nnns |
| 773 | 1 | 8 | |g volume:109 |g year:2024 |g number:4 |g day:01 |g month:04 |g pages:1149-1162 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3324/haematol.2023.282898 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 109 |j 2024 |e 4 |b 01 |c 04 |h 1149-1162 | ||